MetaCap

Boundless Bio (BOLD) vs Lifevantage (LFVN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Boundless Bio (BOLD) has outperformed Lifevantage (LFVN) over the past year, gaining 105.3% versus a loss of 35.5%. Boundless Bio is the larger company by market cap ($54.8 million vs $52.6 million), about 1.0 times the size. Lifevantage pays a dividend yielding 4.58%, while Boundless Bio does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLD+105.31%LFVN-35.46%
+176%+64%-48%
Nov 21, 20251 yearNov 20, 2026
BOLD-83.72%LFVN-31.40%
+339%+113%-113%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLD versus LFVN key metrics
MetricBOLDLFVN
Share price$2.32$4.15
Market cap$54.78M$52.63M
1-day change-2.52%-15.13%
YTD return+93.33%-32.63%
1-year return+105.31%-35.46%
5-year return—-38.52%
P/E ratio (TTM)—19.76
Forward P/E—27.67
EPS (TTM)$-2.46$0.21
Dividend yield0.00%4.58%
Annual dividend$0.00$0.19
Revenue (latest FY)—$182.59M
Revenue growth (YoY)—-20.10%
Net income (latest FY)$-58.20M$5.07M
Gross margin—77.56%
Operating margin—3.34%
Net margin—2.78%
52-week high$3.16$11.71
52-week low$0.961$3.90
Distance from 52-week high-26.68%-64.56%
Analyst consensusnonenone
Avg. price target upside+72.41%+80.72%
Average volume131.34K45.72K
Shares outstanding23.61M12.68M
Employees28209
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BOLD has outperformed LFVN by 140.8 percentage points over the past year.
  • Lifevantage offers a meaningfully higher dividend yield (4.58% vs 0.00%).

About Boundless Bio

BOLD stock →

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Lifevantage

LFVN stock →

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

Health Care · Biotechnology: Pharmaceutical Preparations · 209 employees

BOLD vs LFVN FAQ

Which is bigger, Boundless Bio or Lifevantage?

Boundless Bio (BOLD) is larger, with a market capitalization of $54.78M compared with $52.63M for Lifevantage (LFVN).

Which stock has performed better over the past year, BOLD or LFVN?

BOLD returned +105.31% over the past 12 months, compared with -35.46% for LFVN (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Boundless Bio or Lifevantage?

Lifevantage pays a dividend yielding 4.58%, while Boundless Bio does not currently pay a regular dividend.

Are Boundless Bio and Lifevantage in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons